指南与共识炎症性肠病

急性重症溃疡性结肠炎:临床试验设计与终点的国际德尔菲共识

Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints.
指南 / 共识 · Clin Gastroenterol Hepatol · 2024-12-15

该国际德尔菲共识由20名具有急性重症溃疡性结肠炎(ASUC)试验设计与实施经验的临床医生参与,采用改良德尔菲法,以至少75%参与者投票「同意」为达成共识标准,共30条声明达成共识,聚焦合格标准、试验设计优化及主要和次要终点推荐。

要点

  • 共识提出ASUC试验的合格标准应涵盖疾病范围、疾病严重程度和既往治疗暴露。
  • 共识建议优化试验设计,包括随机化、分层、皮质类固醇处理和评估时机。
  • 共识推荐主要和次要终点,并定义关键疗效结局:临床和内镜缓解与应答、治疗失败、生活质量。

核心结论

  • 过去十年治疗中重度溃疡性结肠炎的药物扩展,尤其是快速起效的Janus激酶抑制剂,令人鼓舞并重新激发了寻找适合ASUC治疗候选药物的兴趣。
  • 该共识为未来ASUC试验提供了框架,以推进药物开发。

研究设计与样本

  • 采用改良德尔菲共识方法,由20名具有国际代表性和ASUC试验设计与实施专业知识的临床医生组成专家组。
  • 共识达成标准为至少75%的参与者对每条声明投票「同意」。

主要发现

  • 共30条声明达成共识并获得批准。
  • 声明集中于提出合适的合格标准(疾病范围、疾病严重程度、既往治疗暴露)、优化试验设计(随机化、分层、皮质类固醇处理、评估时机)以及推荐主要和次要终点并定义关键疗效结局(临床和内镜应答与缓解、治疗失败、生活质量)。

关键数值与推荐

  • 共识达成阈值:至少75%的参与者投票「同意」。
  • 共30条声明达成共识并获得批准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of trial design-this impedes clinical research efforts to identify novel therapies. The objective of this initiative was to achieve the first consensus and provide clear position statements on ASUC trial design. METHODS: A modified Delphi consensus approach was employed with a panel of 20 clinicians with international representation and expertise in ASUC trial design and delivery. Agreement was defined as at least 75% of participants voting as "agree" with each statement. RESULTS: In total, 30 statements achieved consensus and were approved. Statements centred on proposing suitable eligibility criteria (disease extent, disease severity, prior therapy exposure), optimizing trial design (randomization, stratification, corticosteroid handling, timing of assessments), and recommending primary and secondary endpoints alongside defining key efficacy outcomes (clinical and endoscopic response and remission, treatment failure, quality of life). CONCLUSIONS: The expansion of drugs to treat moderate-severe ulcerative colitis over the past decade, particularly the rapidly acting Janus kinase inhibitors, is promising and has reignited the interest in identifying suitable therapeutic candidates for ASUC. Clinical trials in this high-risk population are challenging to conduct and this consensus provides a framework for future trials to advance drug development.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Honap S, Jairath V, Sands BE, et al. Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints. Clin Gastroenterol Hepatol. 2024. PMID: 39681225. doi:10.1016/j.cgh.2024.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。